Photo of Goutham Narla
Goutham Narla, MD, PhD
    • Positions
    • ADJUNCT ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
    • ADJUNCT ASSISTANT PROFESSOR | Medicine, General Internal Medicine
    • Language
    • English

Clinical Interests: Medical Genetics, Cancer Genetic Counseling, Hereditary Cancer Syndromes, Genetic Testing

Since first discovering the KLF6 gene as a Mount Sinai medical student, Goutham Narla, MD, PhD continues to lay the groundwork for improving diagnosis and treatment of metastatic cancers.  Find out more in Inside Mount Sinai.

Dr. Narla has been involved in the identification and characterization of the KLF6 gene and its role in cancer development and progression. Dr. Narla was the first to identify that KLF6 was a tumor suppressor gene in cancer with his mentor Dr. Scott Friedman. He then went on to identify and characterize the oncogenic splice variant KLF6-SV1 in several different malignancies. His work on the molecular alterations underlying the development and progression of cancer could lay the groundwork for the better diagnosis and treatment of this deadly disease.

Dr. Narla is a recent graduate of the MSTP program at the Mount Sinai School of Medicine. He completed his PhD training with Dr. Scott Friedman, Chief of Liver Diseases. Goutham is now an Assistant Professor in the Departments of Genetics and Genomic Sciences and Medicine at the Mount Sinai Hospital. He is also Director of Physician Scientist Training for the Residency Program and Director of Medical Student Professional Development and Residency Planning.

Dr. Narla's laboratory focuses on the identification and characterization of the genes and pathways involved in cancer metastasis. By testing the functional role of the KLF6 tumor suppressor gene and its oncogenic splice variant KLF6-SV1, Dr. Narla has identified new signaling pathways regulated by this gene family and provided new insight into cancer diagnosis, prognosis and treatment.

Dr. Narla has won numerous awards including the Harold Lamport Biomedical Research Prize, a Howard Hughes Medical Student Research Fellowship, and the Graduate Research Achievement Award. He was recently award a grant from the Howard Hughes Medical Institute to continue his work on the molecular mechanisms underlying prostate cancer metastasis.


PhD, The Mount Sinai School of Medicine